Status:
COMPLETED
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
Lead Sponsor:
Daiichi Sankyo
Conditions:
Thrombosis
Hip Replacement
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
Eligibility Criteria
Inclusion
- 18 years of age or older; male or female.
- Able to provide written informed consent.
- Must be scheduled for elective unilateral total hip replacement surgery. Only primary surgeries accepted.
- If female, must be either one year post-menopausal, surgically sterile, or using medically accepted contraceptive measures as judged by the Investigator and in accordance with local regulatory requirements.
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
903 Patients enrolled
Trial Details
Trial ID
NCT00398216
Start Date
May 1 2006
End Date
June 1 2007
Last Update
February 26 2019
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Hartford, Connecticut, United States
2
Sarasota, Florida, United States
3
Austin, Texas, United States
4
Ajax, Ontario, Canada